Sirio Pharma Co., Ltd.

SZSE:300791 Stock Report

Market Cap: CN¥6.4b

Sirio Pharma Future Growth

Future criteria checks 3/6

Sirio Pharma is forecast to grow earnings and revenue by 21.9% and 14.4% per annum respectively. EPS is expected to grow by 21.7% per annum. Return on equity is forecast to be 17.4% in 3 years.

Key information

21.9%

Earnings growth rate

21.7%

EPS growth rate

Personal Products earnings growth21.0%
Revenue growth rate14.4%
Future return on equity17.4%
Analyst coverage

Good

Last updated26 Sep 2024

Recent future growth updates

Recent updates

Is Now The Time To Put Sirio Pharma (SZSE:300791) On Your Watchlist?

Oct 14
Is Now The Time To Put Sirio Pharma (SZSE:300791) On Your Watchlist?

The Market Lifts Sirio Pharma Co., Ltd. (SZSE:300791) Shares 27% But It Can Do More

Sep 30
The Market Lifts Sirio Pharma Co., Ltd. (SZSE:300791) Shares 27% But It Can Do More

Is Sirio Pharma (SZSE:300791) Using Too Much Debt?

Sep 23
Is Sirio Pharma (SZSE:300791) Using Too Much Debt?

Sirio Pharma Co., Ltd.'s (SZSE:300791) Prospects Need A Boost To Lift Shares

Aug 01
Sirio Pharma Co., Ltd.'s (SZSE:300791) Prospects Need A Boost To Lift Shares

Sirio Pharma (SZSE:300791) Will Be Hoping To Turn Its Returns On Capital Around

Jun 30
Sirio Pharma (SZSE:300791) Will Be Hoping To Turn Its Returns On Capital Around

Is Sirio Pharma (SZSE:300791) A Risky Investment?

Jun 12
Is Sirio Pharma (SZSE:300791) A Risky Investment?

An Intrinsic Calculation For Sirio Pharma Co., Ltd. (SZSE:300791) Suggests It's 24% Undervalued

Apr 24
An Intrinsic Calculation For Sirio Pharma Co., Ltd. (SZSE:300791) Suggests It's 24% Undervalued

Sirio Pharma (SZSE:300791) Seems To Use Debt Quite Sensibly

Mar 06
Sirio Pharma (SZSE:300791) Seems To Use Debt Quite Sensibly

Earnings and Revenue Growth Forecasts

SZSE:300791 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20265,758584N/A8564
12/31/20255,046484N/A7135
12/31/20244,356393N/A5885
6/30/20244,028334-82361N/A
3/31/20243,831315-155276N/A
12/31/20233,582281-66386N/A
9/30/20233,22222113393N/A
6/30/20232,94120464370N/A
3/31/20232,78822734344N/A
1/1/20232,507212151445N/A
9/30/20222,40920812388N/A
6/30/20222,315196-74397N/A
3/31/20222,283189-72461N/A
12/31/20212,369232-183341N/A
9/30/20212,361272-96384N/A
6/30/20212,316279-32367N/A
3/31/20212,216265-52257N/A
12/31/20202,06725796320N/A
9/30/20201,86520985272N/A
6/30/20201,71017840203N/A
3/31/20201,55415645206N/A
12/31/20191,58014365232N/A
9/30/20191,62518679236N/A
12/31/20181,595203-56183N/A
12/31/20171,330104N/A49N/A
12/31/2016786704N/A-98N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 300791's forecast earnings growth (21.9% per year) is above the savings rate (2.9%).

Earnings vs Market: 300791's earnings (21.9% per year) are forecast to grow slower than the CN market (23.7% per year).

High Growth Earnings: 300791's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 300791's revenue (14.4% per year) is forecast to grow faster than the CN market (13.5% per year).

High Growth Revenue: 300791's revenue (14.4% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 300791's Return on Equity is forecast to be low in 3 years time (17.4%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y